Asset Details
Do you wish to reserve the book?
Systemic Pharmacokinetics and Cellular Pharmacology of Zidovudine in Human Immunodeficiency Virus Type 1—Infected Women and Newborn Infants
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Systemic Pharmacokinetics and Cellular Pharmacology of Zidovudine in Human Immunodeficiency Virus Type 1—Infected Women and Newborn Infants
Do you wish to request the book?
Systemic Pharmacokinetics and Cellular Pharmacology of Zidovudine in Human Immunodeficiency Virus Type 1—Infected Women and Newborn Infants
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Systemic Pharmacokinetics and Cellular Pharmacology of Zidovudine in Human Immunodeficiency Virus Type 1—Infected Women and Newborn Infants
1999
Overview
Systemic and intracellular pharmacokinetics of zidovudine were determined for 28 human immunodeficiency virus type 1—infected pregnant women and their newborn infants. Plasma zidovudine and intracellular zidovudine monophosphate and triphosphate concentrations were determined in serial maternal samples and cord blood at delivery. Higher levels of cord blood zidovudine were associated with lower maternal zidovudine clearance and longer infusion times. Median levels of zidovudine monophosphate and triphosphate in maternal (1556 and 67 fmol/106 cells) and cord (1464 and 70 fmol/106 cells) blood were similar but highly variable. Intersubject pharmacokinetic variability for zidovudine is substantial, but intravenous therapy provides plasma concentrations and intracellular zidovudine triphosphate levels consistent with high antiviral activity. The substantial amount of intracellular zidovudine triphosphate in cord blood provides an explanation for the clinical success of zidovudine in reducing vertical transmission. Studies of simpler oral regimens of zidovudine can now be evaluated regarding the ability to achieve these pharmacologic end points associated with highly effective parenteral therapy.
Publisher
The University of Chicago Press,University of Chicago Press,Oxford University Press
Subject
/ Adult
/ Anti-HIV Agents - pharmacokinetics
/ Anti-HIV Agents - therapeutic use
/ Antibiotics. Antiinfectious agents. Antiparasitic agents
/ Biological and medical sciences
/ Blood
/ Female
/ HIV
/ HIV 1
/ HIV Infections - drug therapy
/ HIV Infections - transmission
/ Human immunodeficiency virus 1
/ Humans
/ Infant
/ Infants
/ Infectious Disease Transmission, Vertical
/ Pharmacology. Drug treatments
/ Pregnancy Complications, Infectious - drug therapy
/ Pregnancy Complications, Infectious - virology
/ Reverse Transcriptase Inhibitors - blood
/ Reverse Transcriptase Inhibitors - pharmacokinetics
/ Reverse Transcriptase Inhibitors - therapeutic use
/ Women
/ Zidovudine - analogs & derivatives
